Recombinant antibody-derived bispecific adapter protein that binds the RevCAR epitope on Allo-RevCAR01-T and CD123 on AML cells, bridging tumor and T cell to trigger CAR signaling; administered as continuous IV infusion.
Recombinant antibody‑derived bispecific adapter that simultaneously binds the RevCAR epitope on Allo‑RevCAR01‑T cells and CD123 on AML cells, bridging T cells and tumor cells to trigger CAR signaling and T‑cell cytotoxicity; enables dose‑tunable, reversible engagement via continuous infusion.
YES
DIRECT
R-TM123 bridges Allo-RevCAR01-T cells to CD123+ AML cells, activating CAR signaling and inducing T cell–mediated cytotoxicity (perforin/granzyme-mediated lysis) of CD123-expressing cells.
Recombinant antibody-derived bispecific adapter protein that binds the RevCAR epitope on Allo-RevCAR01-T and CD123 on AML cells, bridging tumor and T cell to trigger CAR signaling; administered as continuous IV infusion.
Recombinant antibody‑derived bispecific adapter that simultaneously binds the RevCAR epitope on Allo‑RevCAR01‑T cells and CD123 on AML cells, bridging T cells and tumor cells to trigger CAR signaling and T‑cell cytotoxicity; enables dose‑tunable, reversible engagement via continuous infusion.
NO
INDIRECT
Bispecific adapter bridges RevCAR-expressing T cells to CD123+ AML cells, activating CAR signaling and T‑cell–mediated lysis of CD123+ tumor cells; RevCAR-epitope–positive T cells are not the cytotoxic target.
Intravenous bispecific monoclonal antibody (anti-BCMA × anti-CD3) that redirects T cells to kill BCMA-expressing malignant plasma cells; also known as REGN5458.
Linvoseltamab is an intravenous bispecific monoclonal antibody (anti-BCMA × anti-CD3) that simultaneously binds BCMA on malignant plasma cells and CD3 on T cells, forming an immunologic synapse that activates and redirects T cells to kill BCMA-expressing myeloma cells through cytotoxic granule release and cytokine-mediated mechanisms.
YES
DIRECT
Anti-BCMA×anti-CD3 bispecific links T cells to BCMA+ cells, activating T-cell cytotoxicity (immunologic synapse, perforin/granzyme release and cytokine-mediated killing).
Intravenous bispecific monoclonal antibody (anti-BCMA × anti-CD3) that redirects T cells to kill BCMA-expressing malignant plasma cells; also known as REGN5458.
Linvoseltamab is an intravenous bispecific monoclonal antibody (anti-BCMA × anti-CD3) that simultaneously binds BCMA on malignant plasma cells and CD3 on T cells, forming an immunologic synapse that activates and redirects T cells to kill BCMA-expressing myeloma cells through cytotoxic granule release and cytokine-mediated mechanisms.
NO
INDIRECT
CD3ε is on T cells; linvoseltamab binds CD3 to activate/recruit T cells that kill BCMA+ myeloma cells via perforin/granzyme and cytokine-mediated cytotoxicity. CD3+ cells are not the targets of killing.
Intravenous monoclonal antibody targeting SLAMF7/CS1 that activates NK cells and mediates ADCC against myeloma cells.
Humanized monoclonal antibody that binds SLAMF7/CS1 on myeloma and NK cells, activating NK cells and promoting Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) to kill SLAMF7-positive myeloma cells.
YES
DIRECT
Elotuzumab binds SLAMF7 on myeloma cells; its Fc engages FcγRIIIa (CD16) on NK cells to trigger ADCC, and it also activates NK cells via SLAMF7, leading to lysis of SLAMF7-positive tumor cells.